HR and breast neoplasm: Similarly, in the EVER‐132‐002 Phase 3 clinical trial (NCT04639986), which became available outside our data lock point, there was an increased rate of toxicity and severe toxicity with SG in UGT1A1*6 (40 subjects) and UGT1A1*28 (18 subjects) heterozygous individuals with HR+/HER2− breast tumors in comparison to 77 wild‐type individuals.34